1,800
Participants
Start Date
January 31, 2026
Primary Completion Date
September 30, 2030
Study Completion Date
September 30, 2030
Gardasil 9 vaccine
Participants with a valid consent will be offered a three-dose Gardasil 9 series if eligible.
Hepatitis B Virus Vaccine(HBV)
Participants who do not demonstrate immunity to Hep B antibody marker in their blood, HBsAb and not HBsAg will be offered a three-dose series of Hep B. vaccine. A blood test will be done six months later to assess vaccine take i.e. immunity. Patients who demonstrate infection with Hep B virus will be referred to their doctor for further management.
Cognitive Behavioral Therapy
Participants who demonstrate signs and symptoms of depression and/or anxiety will be offered individual behavioral management services. This consists of weekly individual sessions by a trained therapist for 8 weeks with option for referral for further management depending on the outcome of the intervention. The positive outcome consists of a change in presenting symptoms determined after administration of the youth risk behavior screen for high school students, and PHQ-9, and Edinburgh post-natal depression screen for women respectively.
National University of Science and Technology, Zimbabwe
OTHER
Eunice Dube
OTHER